The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial
OpenAlex – March 21, 2025
Source: OpenAlex
Summary
Patients with major depression experienced a significant boost in optimism following psilocybin therapy. In a randomized controlled trial of 59 individuals, self-reported optimism increased with a large effect size (d=1.1) after two psilocybin doses, compared to no change with escitalopram. Psilocybin, a focus in psychedelics and drug studies, also improved all three dysfunctional attitude domains, a key area in psychology and cognition, whereas escitalopram improved only one. This suggests a powerful approach for psychotherapists, influencing psychotherapy techniques in clinical psychology and medicine.
Abstract
Abstract Background Patients with Major Depressive Disorder (MDD) have more dysfunctional attitudes and pessimism than healthy individuals and these biases are correlated with depression severity. Psilocybin has demonstrated sustained remission in MDD. Methods Secondary analysis of a two-arm, randomized controlled trial ( ClinicalTrials.gov Identifier: NCT03429075 ) assessing the effect of psilocybin therapy versus escitalopram on ‘maladaptive’ cognitive biases relevant to the construct of depression. Psilocybin group participants received two 25mg doses and escitalopram group received three weeks of daily 10mg, increased to 20mg for a following three weeks. Primary outcomes in this analysis were post-treatment changes in biases at six weeks compared with baseline, as measured using three validated psychological scales. Findings Fifty-nine MDD patients were randomly allocated to the psilocybin (n=30) or escitalopram (n=29) groups. Self-reported optimism showed a large and significant increase six-weeks after psilocybin treatment ( M diff =6·63 p <0·0001; 95% CI [4·06, 9·20], d= 1·1), whereas there was no change following escitalopram ( M diff =1·52, p =0·205; 95% CI [−0·59, 3·62], d= 0·4). Behavioral results found that patients were more optimistic about desirable life events after psilocybin treatment ( M diff =0·16, p =0·0002; 95% CI [0·08, 0·23], d= 1·1), but they were also less pessimistic about negative life events after escitalopram treatment ( M diff =0·07, p =0·018; 95% CI [0·01, 0·13], d= 0·5). We found improvements in all three domains of dysfunctional attitudes following psilocybin treatment: achievement ( M diff =10·37, p <0·0001; 95% CI [6·38, 14·53], d= 1·0); dependency ( M diff =7·97, p <0·0001; 95% CI [4·00, 11·93], d= 0·9) and self-control ( M diff =6·40, p =0·0006; 95% CI [2·60, 10·20], d= 0·8)), whereas only the achievement domain improved after escitalopram ( M diff =4·10, p =0·005; 95% CI [1·35, 6·86], d= 0·6). Interpretation These results suggest that two high-dose sessions with psilocybin therapy are superior to a six-week daily course of a selective serotonin-reuptake inhibitor antidepressant, in remediating negative cognitive biases in depression. Funding Supported by a private donation from the Alexander Mosley Charitable Trust and by the founding partners of Imperial College London’s Centre for Psychedelic Research. Author Contribution RCH conceptualized the study design and RCH and DJN oversaw the trial. TL plotted and analysed the data. TL and JH interpreted the data. JH wrote the manuscript and TL and RCH provided edits. Transparency Declaration The lead author and manuscript guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Research Material Availability Research materials are available from the corresponding author, [JH], upon reasonable request.